

Office of Combination Products: Roles and Progress

Consensus Summit:
Combination Product Regulatory Issues
RAPS – January 12, 2005

Mark D. Kramer
Director, Office of Combination Products

Overview

- What do we do?
- How do we do it?
- What have we done so far?
- What's next.....

What do we do?

- Make jurisdictional determinations
- Oversee premarket review
- Oversee postmarket regulation
- Resolve disputes
- Develop policy, guidance and regulations
- Serve as resource for industry and review staff
- Outreach
- Report to Congress
- Special Initiatives

Jurisdictional Determinations

Formal

Or

Informal

We strive for transparency

How do we do it?

- Requests for Designation – 67 last year
100% on time !!
- Informal Decisions for many products – phone, email, pre-RFD's
- Primary Mode of Action Rule
- Jurisdictional Updates
- Published ~70 Jurisdictional Determinations
- Resolve appeals of TRG determinations
- Monthly Meetings with Jurisdictional Officers

Jurisdictional Determinations

What's Next....

- Finalize PMOA rule
- Define chemical action
- Publish more jurisdictional updates
- Publish more jurisdictional determinations
- Intercenter Agreements
- ...and more

Premarket Review

Whatever it takes to ensure
**“timely
and effective”**
premarket review of combination
products

How do we do it?

- SOP for intercenter consultation process
- Establish and clarify regulatory pathways
- Establish and facilitate intercenter working groups and internal MOU's
- Facilitate meetings with sponsors
- Monitor and facilitate the consultation process (> 200 in FY04)

How do we do it, more

- Monitor combination product review timeliness
- Advise sponsors and review staff
- Provide training and reviewer tools
- Check classification of all submissions as combination products

Premarket Review

What's Next...

- One Application or Two
- Automated Consultation Tracking System
- Cross Labeling
- Post Approval Changes
- Labeling Format & Content
- Submission Format & Content
- ...and more

Postmarket Regulation

Ensure
**“consistent and
appropriate”**
postmarket regulation

How do we do it?

- GMP Guidance
- Identify appropriate regulatory mechanisms
- Coordinate Centers and Field Offices

Postmarket Regulation

What's Next...

- Adverse Event Reporting Guidance
- Promotion & Advertising
- Registration & Listing
- ...and more

Dispute Resolution

Facilitate resolution of ...

- disputes about the timeliness of premarket review of combination products
- other disputes or disagreements

How do we do it?

- Dispute Resolution Guidance
- Meetings
- Phone Calls
- Email

Dispute Resolution

What's Next...

- Final Dispute Resolution Guidance

Policy, Guidance, and Regulations

Review and update

- guidances
- agreements
- practices

Issue

- guidances
- regulations

How do we do it?

- PMOA rule –definition and assignment algorithm
- Jurisdictional Updates
- Jurisdictional Determinations
- Guidance: User Fees, GMP's, Dispute Resolution
GGP Process – draft, comments, final
- Meetings: internal and external stakeholders

Policy, Guidance, and Regulations

What's Next...

- Finalize PMOA Rule
- One Application or Two
- Adverse Event Reporting
- Cross Labeling
- Chemical Action
- More jurisdictional updates
- More jurisdictional determinations
- Intercenter Agreements
- ...and more

Resource for Industry and Review Staff

Wide range of inquiries on
assignment
and
combination product
regulation

How do we do it?

- Phone
- Email
- Meetings
- Web
- FAQ

Resource for Industry and Review Staff

What's Next...



keep going!

Outreach

Training
and
Outreach

How do we do it?

- Presentations
- Courses (e.g., Introduction to CDER for CDRH Reviewers)
- Web
- Public Meetings

Outreach

What's Next...

Activities already planned for **2005!!**

Report to Congress

Annual Report

- Activities and Impacts
- Data on

Assignment

Receipt of Marketing Applications

Review of Marketing Applications

How do we do it?

- OCP Activities Tracking
- Combination Product Categorization
- Monthly Monitoring of Center activities
- Reports Posted on FDA Website

Report to Congress

What's Next...

FY04 Report coming soon!

Special Initiatives

- Pharmacogenomics
- Novel Drug Delivery
- Tissue Engineering

How do we do it?

Member of

- pharmacogenomics working group
- novel drug delivery working group

Meetings with

- tissue engineering community

Special Initiatives

What's Next...

- Guidance document on pharmacogenomic Dx/Tx co-development
- Guidance document on novel drug delivery systems
- CBER-CDRH joint review team for tissue engineered medical products


Anything Else?

- Evaluate impact of new policies on combination products
- Continued stakeholder input, outreach and training

...and more

OCP Website:

<http://www.fda.gov/oc/combination/>



U.S. Food and Drug Administration



[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#)

Office of Combination Products

[Overview of the Office of Combination Products](#)

[Definition of a Combination Product](#)

Product Jurisdiction/Assignment of Combination Products:

[Definition of the Primary Mode of Action of a Combination Product](#) [PDF 63KB] -- [Comment Period Extended](#) [PDF 96KB]

Combination Products Primary Mode of Action (PMA) Proposed Rule: May 7, 2004, Federal Register - [Presentation](#)

- [Instructions for Submitting a Request for Designation \(RFD\)](#)
- [Assignment of Combination Products/Product Jurisdiction Program - Final Rule \(June 23, 2003\)](#)
- [Jurisdictional Updates](#)
 - [Jurisdictional Determinations](#)
 - [Drug-Biologic Combination Products](#)
 - [Human Demineralized Bone Matrix](#)
 - [Drug-Eluting Cardiovascular Stents](#)
 - [Dental Prophylaxis Pastes with Drug Components](#)
- [Transfer of Therapeutic Biological Products to the Center for Drug Evaluation and Research](#)
- [Intercenter Agreements](#)
- [FY04 OCP Review Performance: Formal Requests for Designation Submitted by Industry - Updated \(October 1, 2003 – September 30, 2004\)](#)

Guidance Documents and Procedures

- [Draft Guidance for Industry and FDA Current Good Manufacturing Practice for Combination Products](#) [PDF 302KB] (September 2004)
- [Draft Guidance for Industry and FDA Staff: Application User Fees for Combination Products](#) [PDF 1.33MB] (September 2004)
- [Draft Guidance for Industry: Combination Products, Timeliness of Premarket Reviews, Dispute Resolution Guidance](#) [PDF 28KB]
- [Selected Guidance Documents Applicable to Combination Products.](#)
- [Intercenter Consultative/Collaborative Review Process](#) [PDF 82KB] [HTML](#)

Reports, Workshops and Presentation

- [Recent OCP Presentations](#)
- [Recent Article in Medical Device & Diagnostic Industry Magazine: Forging New Regulatory Pathways at FDA](#)
- [Office of Combination Products: Annual Report to Congress](#) [PDF 251KB] [HTML](#)
- [Progress Reports to Stakeholders](#)
- [Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical and Regulatory Challenges: Summary of FDA Workshop \(July 8, 2003\)](#)
- [November 25, 2002 Public Hearing on Regulation of Combination Products](#)
 - [Federal Register Notice](#)
 - [Agenda](#) and Presentations
 - [Transcript of Nov. 25, 2002 Public Hearing -](#) [PDF 213KB] [HTML](#)
- [Regulation of Combination Products: FDA Employee Perspectives](#) [PDF 74KB] [HTML](#)

What's New

- **NEW!** [Recent OCP Presentations](#)
- **NEW!** [Recent Article in Medical Device & Diagnostic Industry Magazine: Forging New Regulatory Pathways at FDA](#)
- [Updated FY04 OCP Review Performance: Formal Requests for Designation Submitted by Industry](#)
- **NEW!** [Draft Guidance for Industry and FDA Current Good Manufacturing Practice for Combination Products](#) [PDF 302KB] (September 2004)
- **NEW!** [Jurisdictional Determinations](#)
- **NEW!** [Draft Guidance for Industry and FDA Staff: Application User Fees for Combination Products](#) [PDF 1.33MB] (September 2004)
- [Recent Examples of Combination Product Approvals](#)
- [FDA Proposes Rule on "Combination" Products \(May 6, 2004\)](#)

Contact Us

We are interested in your comments and suggestions about combination products issues. Please contact:

Mark D. Kramer, Director
Office of Combination Products
Food and Drug Administration
15800 Crabbs Branch Way
(HFG-3)
Suite 200

Contact Us

Office of Combination Products
15800 Crabbs Branch Way (HFG-3)
Rockville, MD 20855
(301) 427-1934
combination@fda.gov
<http://www.fda.gov/oc/combination/>